Evaluating trastuzumab in the treatment of HER2 positive breast cancer

Jaques, Ryan; Xu, Sam; Matsakas, Antonios

Abstract

© 2020, Histology and Histopathology. All rights reserved. The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.

Citation

Jaques, R., Xu, S., & Matsakas, A. (2020). Evaluating trastuzumab in the treatment of HER2 positive breast cancer. Histology and Histopathology, 35(10), 1059-1075. https://doi.org/10.14670/HH-18-221

• Journal Article Type: Review
• Acceptance Date: Apr 23, 2020
• Online Publication Date: Dec 4, 2020
• Publication Date: 2020-10
• Deposit Date: May 25, 2022
• Publicly Available Date: Jun 23, 2022
• Journal: Histology and Histopathology
• Print ISSN: 0213-3911
• Electronic ISSN: 1699-5848
• Publisher: Universidad de Murcia
• Peer Reviewed: Peer Reviewed
• Volume: 35
• Issue: 10
• Pages: 1059-1075
• DOI: https://doi.org/10.14670/HH-18-221
• Keywords: Breast cancer; Herceptin; Trastuzumab; Immunotherapy; HER2
• Public URL: https://hull-repository.worktribe.com/output/3681892